Genes, proteins, and neurotoxins involved in Parkinson’s disease
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 3×
“In the last stage (stage 6), nearly the entire neocortex is involved (Braak et al., 2002, 2003).”
BackgroundMethodHershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The gene product was named “parkin” ( Kitada et al., 1998).”
BackgroundInfluentialChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 3×
“In fact, it has been shown that an -synuclein locus triplication causes PD (Singleton et al., 2003).”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 2×
“Since parkin is localized to the microsomal fractions, as well as to the cytosol—and Golgi fraction (Shimura et al., 1999), an endoplasmic reticulum (ER) associated protein degradation appears conceivable.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429 · cited 1×
“A role for autophagy is supported by the presence of -synuclein in organelles with the ultrastructural features of autophagic vesicles (Webb et al., 2003), but to date it is not clear to which extent autophagy plays a role in the degradation of misfolded -synuclein.”
BackgroundIwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316 · cited 2×
“…expressed in areas of the adult CNS that display synaptic plasticity, including the cerebral cortex, the hippocampus, the amygdala and the olfactory bulb (Maroteaux and Scheller, 1991; Iwai et al., 1995), it is possible that -synuclein is also involved in synaptic plasticity in the mammalian brain.”
BackgroundNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Joazeiro, C. A. P., & Weissman, A. M. (2000) · Cell · doi:10.1016/s0092-8674(00)00077-5 · Cited by 1,249 · cited 1×
“Similar to other E3 RING-finger proteins (Joazeiro and Weissman, 2000), the RING-finger region of parkin confers the binding site for E2s (Giasson and Lee, 2001).”
BackgroundCleeter, M. W. J., Cooper, J. M., Darley-Usmar, V. M., Moncada, S., & Schapira, A. H. V. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00424-2 · Cited by 1,241 · cited 1×
“NO also inhibits the mitochondrial respiratory chain (Cleeter et al., 1994) and enhances MPP+ inhibition of complex I. Nitric oxide synthase inhibitors protect against MPTP-induced neurotoxicity in rodents (Smith et al., 1994; Schulz et al., 1995) and prevent MPTP-induced parkinsonism in baboons…”
BackgroundShimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., & Takahashi, R. (2001) · Cell · doi:10.1016/s0092-8674(01)00407-x · Cited by 1,050
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982 · cited 5×
“The absence of LBs in PD patients with parkin mutations suggests that parkin might be required for the formation of LBs (Zhang et al., 2000b; Chung et al., 2001a).”
BackgroundInfluentialParkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913
Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., et al. (1996) · Science · doi:10.1126/science.274.5290.1197 · Cited by 788
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773 · cited 2×
“…these different stages indicate that the evaluation of the substantia nigra is not sufficient for the neuropathological evaluation of questionable PD cases, since the substantia nigra is not the first structure in the brain, in which PD-related abnormalities develop (Del Tredici et al., 2002).”
BackgroundChung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1144 · Cited by 750 · cited 10×
“Indeed, parkin has been shown to ubiquitinate LBlike inclusion bodies (Chung et al., 2001a) and to protect against the toxicity associated with -synuclein (Petrucelli et al., 2002).”
BackgroundInfluentialMasliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598 · cited 3×
“In cell-free systems, a dose-dependent inhibition of TH by -synuclein has been observed (Perez et al., 2002).”
BackgroundInfluentialHaas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K., & Mizuno, Y. (1998) · Neurology · doi:10.1212/wnl.51.3.890 · Cited by 370
Wakabayashi, K., Hayashi, S., Kakita, A., Yamada, M., Toyoshima, Y., Yoshimoto, M., & Takahashi, H. (1998) · Acta Neuropathologica · doi:10.1007/s004010050918 · Cited by 347 · cited 2×
“Since -synuclein is one of the major components of LBs (Iwatsubo, 2003), the process of LB formation can be divided into several stages (Wakabayashi et al., 1998; Takahashi and Wakabayashi, 2001).”
BackgroundThe rat brain synucleins; family of proteins transiently associated with neuronal membrane
Maroteaux, L., & Scheller, R. H. (1991) · Molecular Brain Research · doi:10.1016/0169-328x(91)90043-w · Cited by 334 · cited 3×
“The subcellular localization of the synucleins has not been established in detail, and suggested sites of action include the presynaptic terminals, the nuclear envelope and the cytoplasm (Maroteaux and Scheller, 1991; Lavedan, 1998).”
BackgroundBehavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285 · cited 2×
“, 2002 ) or mutations in both positions ( Richfield et al., 2002).”
BackgroundRathke‐Hartlieb, S., Kahle, P. J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haass, C., & Schulz, J. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00366.x · Cited by 128 · cited 4×
“Mice overexpressing mutant A53T human alphasynuclein, under the control of the prion promotor (Giasson et al., 2002; Lee et al., 2002), showed behavioral and neuronal dysfunction accompagnied by aggregate formation, but not in the substantia nigra (Giasson et al., 2002; Lee et al., 2002), In addition, mice that overex…”
BackgroundInfluentialDecreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease
Ferrarese, C., Tremolizzo, L., Rigoldi, M., Sala, G., Brighina, L., Ricci, G., Albizzati, M. G., Piolti, R., Crosti, F., Dalpr�, L., et al. (2001) · Neurological Sciences · doi:10.1007/s100720170049 · Cited by 39 · cited 1×
“In addition, a decreased platelet glutamate uptake has been evidenced in patients with PD (Ferrarese et al., 2001).”
Background
Cited by
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
“Also depicted are ways in which potential defects in the system cause PD. UCHL1, one of the most abundant proteins in brain (up to 2% of total brain protein), releases free ubiquitin and allows the cycle to continue (von Bohlen und Halbach et al. 2004).”
BackgroundWagner, K. M., McReynolds, C. B., Schmidt, W. K., & Hammock, B. D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.006 · Cited by 270
Kim, Y., Park, H., Lee, G., Bang, O. Y., Ahn, Y. H., Joe, E., Kim, H. O., & Lee, P. H. (2009) · Glia · doi:10.1002/glia.20731 · Cited by 251
“…in PD may involve several molecular and cellular events, including oxidative stress, proapoptotic mechanisms, mitochondrial dysfunction, and the accumulation of toxic proteins resulting from dysfunction of the protein degradation system (Moore et al., 2005; von Bohlen und Halbach et al., 2004).”
Background
Metadata
- Authors
- Halbach, O. V. B. U., Schober, A., & Krieglstein, K.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 73
- Issue
- 3
- Pages
- 151-177
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2002288323
- Cited by
- 181
- References
- 36
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.